Navigation Links
Ranbaxy Gets USFDA Nod For Simvastatin

Pharma major Ranbaxy Laboratories Ltd has received approval from the USFDA for manufacturing and marketing cholesterol-lowering Simvastatin Tablets in the US market. //

The company said it has received the approval for marketing the drug in strengths of 80mg with 180 day exclusivity.

Simvastatin, currently marketed as 'Zocor' in the US, has been found to be bioequivalent by the FDA Office of Generic Drugs. The total annualized market sales for Simvastatin is 4.6 billion dollars, out of which the 80mg strength accounts for 513 million dollars.

"We anticipate significant benefits and value from our Simvastatin formulation to both patients and prescribers," Ranbaxy CEO and Managing Director Malvinder Mohan Singh said.

The drug is indicated in the treatment of patients with coronary heart disease, hypercholesterolemia requiring modifications of lipid profiles and adolescent patients with Heterozygous Familial Hypercholesterolemia (HeFH).

"We expect to launch Simvastatin 80mg on an exclusive basis immediately. We believe that by offering an affordably priced generic alternative, we will have a positive impact on the cost of healthcare for patients who have or are at high risk of coronary heart disease," Ranbaxy Pharmaceuticals Inc Vice President of sales and marketing Jim Meehan said.

(Source:PTI News)
'"/>




Page: 1

Related medicine news :

1. Ranbaxy joins hand with Cipla to co-market ciprofloxacin
2. Ranbaxy gets US FDA approval for Lisinopril
3. Ranbaxy Labs Entry Into Anti-Acne Market
4. Ranbaxy trying to make inroads in herbal drugs market
5. Lamivudine Manufactured By Ranbaxy gets the nod from the US FDA
6. Ranbaxy Pharmaceuticals Inc awarded the prestigious outstanding supplier award received from Wal-Mart
7. Ranbaxy opens Drug discovery centre in Gurgaon
8. Ranbaxy Laboratories All Set To Export Bird Flu Vaccines
9. SRL Ranbaxy offers quicker bird flu diagnostic test
10. Diagnostic Test Launched by Ranbaxy for En Masse Screening of Bird Flu
11. Ranbaxy Launches Once-a-day Inhaler For Asthma Patients
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/28/2017)... ... March 28, 2017 , ... Columbus OH. Dr. Justin ... one of few medical professionals in the country to sit on the 2017 National ... Aesthetics, in just 2 years Dr. Harper helped propel the clinic from a small ...
(Date:3/28/2017)... Los Angeles, CA (PRWEB) , ... March 28, ... ... Pediatrics credential, which will be offered by the American Association of Integrative Medicine ... Saturday presentations for healthcare providers at the AutismOne 2017 Conference in Colorado Springs. ...
(Date:3/28/2017)... ... , ... Public relations pros work hard to earn placements and build ... many results are clear, much of PR is hard to quantify. Goal-setting and measurement ... measurement, firms should always take an all-inclusive approach that takes both traditional and non-traditional ...
(Date:3/28/2017)... (PRWEB) , ... March 28, 2017 , ... With expansion ... Marshallville, Georgia, in early March. , The seed processing plant opened in Marshallville in ... since 2016. The new office allows opportunity for transition of Patten Seed operations to ...
(Date:3/28/2017)... Albertson, NY (PRWEB) , ... March 28, 2017 , ... Oily skin is a common ... with Advanced Dermatology has a lot to offer to the discussion of dealing ... good news is that there are many home remedies that can help remove the oily ...
Breaking Medicine News(10 mins):
(Date:3/28/2017)... 2017 "Chemotherapy Induced Neutropenia (CIN) – Market Insights, Epidemiology ... global market trends of the Chemotherapy Induced Neutropenia for the seven ... Europe ( France , Germany ... , UK) and Japan , as well as ... the world (RoW). The Report covers the therapeutics market ...
(Date:3/28/2017)... 28, 2017  Rosen Law Firm, a global investor ... action lawsuit on behalf of purchasers of Kitov Pharmaceutical ... and/or traceable to Kitov,s initial public offering on or ... open market from November 20, 2015 through February 3, ... seeks to recover damages for Kitov investors under the ...
(Date:3/28/2017)... March 28, 2017  Orexigen Therapeutics, Inc. (Nasdaq: ... for the fourth quarter and year ended December 31, ... of transformational progress for Orexigen, beginning with the re-acquisition ... Commencing early March, the team at Orexigen demonstrated remarkable ... which reshaped and strengthened our Company while rewarding us ...
Breaking Medicine Technology: